

Article

Interactions of Mycotoxin Alternariol with Cytochrome P450 Enzymes and OATP Transporters

Eszter Fliszár-Nyúl ^{1,2,†}, Orsolya Ungvári ^{3,4,†}, Ágnes Dombi ¹, Csilla Özvegy-Laczka ³ and Miklós Poór ^{1,2,*} ¹ Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary² Food Biotechnology Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary³ Drug Resistance Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary⁴ Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Pázmány P. stny. 1/C, H-1117 Budapest, Hungary

* Correspondence: poor.miklos@pte.hu

† These authors contributed equally to this work.

Abstract: Alternariol (AOH) is an emerging mycotoxin produced by *Alternaria* strains. The acute toxicity of the mycotoxin is low; however, chronic exposure to AOH may result in the development of endocrine disruptor and/or carcinogenic effects. The toxicokinetic properties of AOH have barely been characterized. Therefore, in this study, we aimed to investigate its interactions with CYP (1A2, 2C9, 2C19, 2D6, and 3A4) enzymes and OATP (1A2, 1B1, 1B3, and 2B1) transporters employing in vitro enzyme assays and OATP overexpressing cells, respectively. Our results demonstrated that AOH is a strong inhibitor of CYP1A2 ($IC_{50} = 0.15 \mu M$) and CYP2C9 ($IC_{50} = 7.4 \mu M$). Based on the AOH depletion assays in the presence of CYP enzymes, CYP1A2 is mainly involved, while CYP2C19 is moderately involved in the CYP-catalyzed biotransformation of the mycotoxin. AOH proved to be a strong inhibitor of each OATP transporter examined ($IC_{50} = 1.9$ to $5.4 \mu M$). In addition, both direct and indirect assays suggest the involvement of OATP1B1 in the cellular uptake of the mycotoxin. These findings promote the deeper understanding of certain toxicokinetic interactions of AOH.

Keywords: alternariol; CYP enzymes; CYP1A2; OATP transporters; OATP1B1

Citation: Fliszár-Nyúl, E.; Ungvári, O.; Dombi, Á.; Özvegy-Laczka, C.; Poór, M. Interactions of Mycotoxin Alternariol with Cytochrome P450 Enzymes and OATP Transporters. *Metabolites* **2023**, *13*, 45. <https://doi.org/10.3390/metabo13010045>

Academic Editor: Miroslava Zhiponova

Received: 14 December 2022

Revised: 19 December 2022

Accepted: 26 December 2022

Published: 28 December 2022



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Mycotoxins are toxic secondary metabolites of filamentous fungi [1]. *Alternaria* species produce more than 70 mycotoxins [2], including alternariol (AOH), which frequently contaminates berries, tomatoes, oilseeds, grapes, and the corresponding products (e.g., tomato pastes, fruit juices, and wines) [3–5]. In previous studies, the genotoxic, immunosuppressive, endocrine disruptor, cytotoxic, and carcinogenic effects of AOH have been reported [4,6,7]. Phase I biotransformation of AOH results in the formation of 2-, 4-, 8-, and 10-hydroxy derivatives [8,9]. Phase II reactions are also involved in the metabolism of AOH: a recent study demonstrated the formation of sulfate conjugates [10], and it is reasonable to hypothesize the production of its glucuronic acid metabolites [9].

Cytochrome P450 (CYP) enzymes contribute to approximately 75% of the phase I biotransformation of xenobiotics [11]. The five human CYP isoforms, which catalyze the majority of these reactions, are CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 [11,12]. Since CYP-catalyzed oxidations typically affect the toxicokinetic and toxicodynamic properties of xenobiotics, these enzymes frequently play a major role in the detoxification or toxic activation of certain compounds. The interactions of some mycotoxins (including aflatoxin B1, ochratoxin A, and zearalenone) with CYP enzymes have been reported [13–15], while only limited data are available regarding AOH. Based on a previous study, AOH is biotransformed by CYP1A1 and 1A2 enzymes and the mycotoxin can increase the expression of CYP1A1 through the activation of aryl hydrocarbon receptor [16].

Solute carrier organic anion transporting polypeptides (OATPs), present in the cell membrane of epithelial and endothelial cells of the human body, are transporters that mediate the cellular uptake of large (>300 Da), negatively charged, or amphipathic organic molecules [17]. Steroid and thyroid hormones, bile acids, prostaglandins, and bilirubin are typical endogenous substrates of OATPs [18]. Furthermore, multispecific members of the OATP family (OATP1A2, OATP1B1, OATP1B3, and OATP2B1) also recognize various xenobiotics, such as drugs (e.g., statins and certain chemotherapeutics), food components (e.g., flavonoids), and toxins (e.g., α -amanitin and ochratoxin A) [19–21]. OATPs 1B1, 1B3, and 2B1 are expressed in human hepatocytes and contribute to the hepatic clearance of their substrates [22]. Furthermore, OATP2B1 and OATP1A2 appear in enterocytes and in the endothelial cells of the blood–brain barrier [23]. These multispecific OATPs are key players in the tissue uptake and clearance of drugs, nutrients, and xenobiotics. Previous studies demonstrated the interaction of the *Aspergillus* mycotoxin ochratoxin A with OATPs [21,24]; however, the effect of AOH on these carriers has not yet been characterized.

In this study, we aimed to investigate the interactions of AOH with CYP (1A2, 2C9, 2C19, 2D6, and 3A4) enzymes and OATP (1A2, 1B1, 1B3, and 2B1) transporters employing in vitro assays with human recombinant enzymes and OATP overexpressing cells, respectively. Our results demonstrated that AOH is a potent inhibitor of CYP1A2, CYP2C9, and the OATPs tested. Furthermore, AOH seems to be a potential substrate for CYP1A2 and OATP1B1. Our findings contribute to the deeper understanding of certain toxicokinetic interactions of AOH.

2. Materials and Methods

2.1. Reagents

Alternariol was purchased from Cfm Oskar Tropitzsch GmbH (Marketredwitz, Germany). CypExpress human recombinant Cytochrome P450 (1A2, 2C9, 2C19, 2D6, and 3A4) kits, CypExpress Control (CYPnull), testosterone, and 6 β -hydroxytestosterone were obtained from Merck (Darmstadt, Germany). CYP1A2 Inhibitor Assay Kit (fluorometric; ab211075) was from Abcam (Cambridge, UK). Diclofenac, 4'-hydroxydiclofenac, S-mephenytoin, 4-hydroxymephenytoin, dextromethorphan, and dextrorphan were purchased from Carbosynth (Berkshire, UK). HPLC grade acetonitrile and methanol were obtained from VWR (Debrecen, Hungary). Nicotinamide adenine dinucleotide phosphate sodium salt and glucose-6-phosphate barium salt were from Reanal (Budapest, Hungary). Stock solution of AOH (40 mM) was prepared in spectroscopic grade dimethyl sulfoxide (DMSO; Fluka, Charlotte, NC, USA) and stored at -20°C .

2.2. Testing the Inhibitory Effect of AOH on CYP450 Enzymes

The potential inhibitory effects of AOH on CYP2C9, 2C19, 2D6, and 3A4 enzymes were tested in vitro employing CypExpress human kits, using the substrates recommended by the U.S. Food and Drug Administration (FDA; <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers>; accessed on 19 December 2022) (diclofenac, S-mephenytoin, dextromethorphan, and testosterone, respectively). The impacts of increasing concentrations of AOH (0.00, 0.05, 0.50, 2.0, 5.0, 10, 25, 30, and 50 μM) were examined on diclofenac 4'-hydroxylation (CYP2C9) [25], S-mephenytoin 4-hydroxylation (CYP2C19) [26], dextromethorphan demethylation (CYP2D6) [20], and testosterone 6 β -hydroxylation (CYP3A4) [27] as described previously, without modifications. In these assays, the substrates and products were quantified by HPLC-UV [28].

CYP1A2 Inhibitor Assay Kit (Abcam; Cambridge, UK) was applied following the manufacturer's description, where the inhibitory action of 0.000, 0.001, 0.010, 0.050, 0.10, 0.20, 0.50, 1.25, 3.0, 10, and 25 μM AOH concentrations were tested.

Solvent controls were also applied in each experiment, DMSO concentrations did not exceed 0.13 v/v%. IC₅₀ values were calculated by sigmoidal fitting (Hill1), using the Origin (version 2018, OriginLab Corporation, Northampton, MA, USA) software.

2.3. Testing the Biotransformation of AOH by CYP450 Enzymes

To test the potential biotransformation of AOH by CYPs, the changes in the concentrations of AOH were examined in the presence of CYP1A2, 2C9, 2C19, 2D6, or 3A4 enzymes. Samples (final volume: 200 μ L) containing AOH (5 μ M), glucose-6-phosphate (500 μ M), nicotinamide adenine dinucleotide phosphate (NADP⁺, 200 μ M), and the enzymes (CypExpress Cytochrome P450 reagents: 15 mg/mL each; including both CYP and glucose-6-phosphate dehydrogenase enzymes) were incubated for 0, 30, 60, 90, and 120 min (700 rpm, 30 °C) in potassium phosphate buffer (0.05 M, pH 7.5). The reaction was stopped by the addition of ice-cold methanol (100 μ L), then the samples were centrifuged (10 min, 14,000 g, room temperature). AOH content of the supernatants was directly analyzed by HPLC-FLD (see details in Section 2.7). As a control, CypExpress Control reagent (CYPnull; 15 mg/mL) was also applied, which is a permeabilized and stabilized dried yeast powder (produced using an empty vector) and processed identically to CypExpress Cytochrome P450 products.

2.4. Generation and Maintenance of OATP Overexpressing Cell Lines

A431 cell lines overexpressing human OATPs (1A2, 1B1, 1B3, or 2B1) and their mock transfected controls were generated earlier [29,30]. A431 cells expressed no or negligible OATPs compared to the overexpressing cell lines. Cells were cultured in Dulbecco's modified Eagle medium (DMEM, Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μ g/mL streptomycin at 37 °C, with 5% CO₂. OATP expression was regularly monitored (based on the transport activity of transfected cells), and the cells were used up to 20 passages.

2.5. Testing the Inhibitory Effect of AOH on OATP Transporter Function

Interaction between OATPs (1A2, 1B1, 1B3, and 2B1) and AOH was measured in an indirect transport assay [30] with pyranine or sulforhodamine 101 as fluorescent probes [29,31]. A431 cell overexpressing OATPs or their mock transfected controls were seeded on 96-well plates one day prior to the measurements in 200 μ L DMEM in 8×10^4 cells/well density. Before the measurement, the medium was removed, and cells were washed three times with 200 μ L PBS (phosphate-buffered saline, pH 7.2) at room temperature. Then the cells were preincubated with 50 μ L uptake buffer (125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl₂, 1.2 mM KH₂PO₄, 12 mM MgSO₄, 25 mM MES, and 5.6 mM glucose, with the pH adjusted using 1 M HEPES and 10 N NaOH, pH 5.5 for OATP1B1/1B3/2B1 and pH 7.4 for OATP1A2) with or without increasing concentrations (0.00, 0.16, 0.31, 0.63, 1.25, 2.5, 5.0, 10, and 20 μ M) of AOH for 5 min. The reaction was started when the probe was added in 10 μ M (pyranine; OATP1B1), 20 μ M (pyranine; OATP2B1 and OATP1B3), or 0.5 μ M (sulforhodamine 101; OATP1A2) final concentrations. Incubation times at 37 °C were 10 min (OATP1A2), 15 min (OATP1B1 and OATP2B1), and 30 min (OATP1B3). The reaction was stopped by removing the supernatant and washing the cells three times with ice-cold PBS. Fluorescence was measured in an Enspire plate reader (Perkin Elmer, Waltham, MA, USA) in Ex/Em wavelengths 460/510 nm for pyranine and 586/605 nm for sulforhodamine 101. Bottom reading was applied with two horizontal (X) and two vertical (Y) points, measurement height was 3 mm with 200 flashes. IC₅₀ values were calculated by sigmoidal fitting (Hill1), using the Origin (version 2018, OriginLab Corporation, Northampton, MA, USA) software.

2.6. Testing the Involvement of OATP1B1 in the Cellular Uptake of AOH

The A431 cell line overexpressing OATP1B1 or mock transfected control were trypsinized, and counted with automated cell counter (TC10, BIORAD, Hercules, CA, USA). The cells were washed with 1 mL buffer (pH 5.5; described above) and centrifuged for 5 min at 1500 g. After the supernatant was removed, 2×10^6 cells in 50 μ L volume of the same buffer were handed out into separate Eppendorf tubes, then 50 μ L of AOH solutions (diluted in buffer, pH 5.5) was added (final concentrations: 2, 5, or 10 μ M). The cells were incubated for 15 min at 37 °C

in shaking water bath. The reaction was stopped with 1 mL ice-cold PBS, after which the tubes were centrifuged for 5 min at 1500 g and 4 °C. The supernatant was removed, and the cells were washed with 1 mL ice-cold PBS, then the cell pellet was stored at −80 °C until analyses.

Before HPLC measurements, cell pellets were dissolved in 100 µL of 1 M NaOH solution with vigorous vortexing. After 15 min sonication, the solution was neutralized with 100 µL of 1 M HCl, then 200 µL acetonitrile was added. Samples were vortexed and centrifuged for 10 min at 14,000 g and 4 °C. Thereafter, the supernatant was directly analyzed with HPLC-FLD (see details in Section 2.7).

2.7. HPLC Analyses

After CYP450 incubations, the product formation rate was investigated using an integrated HPLC system (Jasco, Tokyo, Japan) built up from an autosampler (AS-4050), a binary pump (PU-4180), and a UV detector (UV-975). Chromatographic data were evaluated employing ChromNAV2 software (Jasco, Tokyo, Japan). Quantitative determinations of 4'-hydroxydiclofenac and diclofenac (CYP2C9), 4-hydroxymephenytoin and mephenytoin (CYP2C19), dextromethorphan and dextrorphan (CYP2D6), as well as testosterone and 6β-hydroxytestosterone (CYP3A4) were carried out as previously reported [28], without modifications.

In CYP experiments, AOH was quantified with the above-described HPLC system, except that a fluorescence detector (FP-920; Jasco, Tokyo, Japan) was applied. Samples (20 µL) were driven through a Phenomenex Security Guard (C18, 4.0 × 3.0 mm) precolumn (Phenomenex, Torrance, CA, USA) linked to a Kinetex EVO-C18 (250 × 4.6 mm, 5 µm; Phenomenex) analytical column with 1.0 mL/min flow rate, at room temperature. For the isocratic elution, a mobile phase with 1 mM phosphoric acid (pH 3.0) and acetonitrile (65:35 v/v%) was applied. AOH was detected at 455 nm ($\lambda_{\text{ex}} = 345 \text{ nm}$). Limit of detection (LOD) and limit of quantification (LOQ) were established as the lowest concentrations when the signal-to-noise ratios were three and ten, respectively. The major validation parameters of this HPLC-FLD method were the following: linearity ($R^2 = 0.997$, in the 100–1000 nM concentration range); LOD = 100 nM; LOQ = 200 nM; intraday precision = 2.9% (n = 7); accuracy = 3.4% (n = 7).

To examine the OATP1B1-mediated uptake of AOH in A431 cells, our recently reported magnesium-sensitized HPLC-FLD method was applied [32]. Briefly, samples (20 µL) were driven through a Security Guard (C8, 4.0 × 3.0 mm; Phenomenex, Torrance, CA, USA) precolumn linked to a Kinetex C8 (100 × 4.6 mm, 5 µm; Phenomenex, Torrance, CA, USA) analytical column. The isocratic elution was performed with 10 mM HEPES buffer (pH 7.0) and acetonitrile (70:30 v/v%) containing 50 mM MgCl₂, using 1.0 mL/min flow rate at room temperature. AOH was quantified using 345 nm and 455 nm excitation and emission wavelengths, respectively. The major validation parameters of this HPLC-FLD method were the following: linearity ($R^2 = 0.999$ in the 20–1000 nM concentration range); LOD = 10 nM; LOQ = 20 nM; intraday precision = 2.2% (n = 7); accuracy = 2.6% (n = 7).

2.8. Testing AOH-OATP Interaction in Competitive Counterflow and Efflux Assays

The assays were performed as described recently [33]. Cells were seeded on 96-well plates one day prior to the measurement. After washing three times with PBS at room temperature, cells were incubated for 15 min with 8-acetoxy-1,3,6-trisulfonypyrene (Ace, 5 µM). After this “preloading” stage, the supernatant was removed, and the cells were incubated with the same amount of the probe (Counterflow assay) or without the probe in buffer pH 5.5 (Efflux assay) in the absence and the presence of AOH for further 20 min. Fixed concentrations of AOH were selected based on the IC₅₀ values determined in the transport inhibition assay. Estrone-3-sulfate (E1S, 50 µM) and formaldehyde (PFA, 0.5%) served as reference substrate and inhibitor, respectively. Cells were washed three times with ice-cold PBS, then NaOH solution (0.1 N, 200 µL/well) was added. After 20 min, fluorescence was measured with an Enspire plate reader in Ex/Em wavelengths 460/510 nm. Bottom reading was applied with two horizontal (X) and two vertical (Y) points, measurement

height was 3 mm with 200 flashes. Fluorescence was compared to the preloaded control incubated with Ace alone, considered as 100%.

2.9. Data Analyses

Data display mean and standard error of the mean (\pm SEM) values, derived from at least three independent experiments. Statistical significance ($p < 0.05$ and $p < 0.01$) was evaluated based on one-way ANOVA test followed by Tukey's post hoc test (version 21, IBM SPSS Statistics, Armonk, NY, USA).

3. Results and Discussion

3.1. Interaction of AOH with CYP Enzymes

The interactions of AOH with CYP enzymes were investigated employing 0 to 50 μ M mycotoxin concentrations. AOH induced the concentration-dependent inhibition of the CYP enzymes tested, except CYP2D6-catalyzed dextromethorphan demethylation, which was not affected even by 50 μ M AOH (Figure 1). It is not surprising because typically amines, which can be protonated under physiological circumstances, can interact with CYP2D6 [34]. Among the CYP enzymes examined, AOH proved to be the most potent inhibitor of CYP1A2 ($IC_{50} = 0.15 \mu$ M), causing statistically significant ($p < 0.01$) and close to complete inhibitions at 0.05 μ M and 10 μ M concentrations, respectively. Furthermore, the mycotoxin strongly inhibited the CYP2C9 enzyme ($IC_{50} = 7.4 \mu$ M), leading to more than an 80% decrease in the product formation at 50 μ M concentration. At 5 μ M concentration, AOH significantly ($p < 0.01$) inhibited CYP2C19; nevertheless, the highest AOH concentration applied (50 μ M) caused only a 55% decrease in 4-hydroxymephenytoin production (Figure 1). Finally, AOH inhibited CYP3A4 enzyme; however, the mycotoxin did not cause a further relevant decrease in the metabolite formation above 10 μ M concentration (approximately 40% inhibition) (Figure 1).




Figure 1. Concentration-dependent inhibitory effects of AOH (0–50 μ M) on CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 enzymes ($n = 3$; * $p < 0.05$, ** $p < 0.01$).

Urolithins are colon metabolites of ellagitannins [35]; they have a very similar chemical structure to *Alternaria* mycotoxins. In agreement with our results, a previous study demonstrated the inhibitory effects of urolithins (e.g., urolithin A, B, and C) on CYP1A2 and CYP1B1 enzymes [36].

The inhibitory actions of certain other mycotoxins on CYP enzymes have also been reported. Zearalenone showed a strong inhibitory effect on CYP2C9-catalyzed tolbutamide hydroxylation ($IC_{50} = 0.54 \mu$ M), while it was only a weak inhibitor of CYP2D6-mediated dextromethorphan *O*-demethylation ($IC_{50} = 55.4 \mu$ M) [37]. T-2 toxin and zearalenone

markedly reduced CYP3A4-catalyzed midazolam hydroxylation in vitro (IC_{50} values were 27.0 and 1.1 μ M, respectively); in addition, zearalenone increased the oral bioavailability of midazolam in pigs [37].

To test the potential biotransformation of the mycotoxin by CYP enzymes, AOH was incubated with CYP1A2, 2C9, 2C19, 2D6, and 3A4. Even after a 120 min incubation, our results demonstrated no relevant changes in AOH levels in the presence of CYP2C9, CYP2D6, and CYP3A4. These incubates showed very similar data to the control (CYPnull) (Figure 2). CYP2C19 caused only a slight decrease in AOH levels, showing a statistically significant difference ($p < 0.01$) only after a 120 min incubation. However, CYP1A2 enzyme induced a concentration-dependent decrease in AOH concentrations, leading to a 16% and 25% depletion of AOH after 60 min and 120 min incubations, respectively (Figure 2).




Figure 2. Time-dependent changes in the concentrations of AOH (5 μ M) in the presence of the different CYP isoenzymes (see experimental details in 2.3; $n = 3$; ** $p < 0.01$). Statistical evaluation was performed compared to the incubation with the same amount of CYPnull (15 mg/mL), which is a permeabilized and stabilized dried yeast powder (produced using an empty vector) and processed identically to CypExpress Cytochrome P450 products.

Based on our current knowledge, this is the first study to examine the inhibitory action of AOH on CYP enzymes. Considering the above-listed data, AOH is a weak inhibitor of CYP2C19 and CYP3A4, while it exerts very strong and moderately strong inhibition on CYP1A2 and CYP2C9 enzymes, respectively (Figure 1). Furthermore, based on these observations, we did not see the relevant involvement of CYP2C9, CYP2D6, and CYP3A4 in the metabolism of AOH. On the other hand, CYP2C19 and mainly CYP1A2 seem to be important CYP enzymes regarding the biotransformation of this mycotoxin (Figure 2). In an earlier study, the CYP-catalyzed biotransformation of AOH was examined using pooled human hepatic microsomes, suggesting the CYP1A-mediated metabolism of AOH with the minor involvement of CYP2C19 and CYP3A4 [38]. Our study confirms the importance of the CYP1A2 and CYP2C19 enzymes.

3.2. Interaction of AOH with OATP Transporters

First, the potential inhibitory impact of AOH on OATP transporters was examined, employing pyranine or sulforhodamine 101, previously documented as fluorescent test substrates [29,31]. As demonstrated in Figure 3, AOH proved to be a potent inhibitor of each OATP tested, showing the strongest inhibitory actions on OATP2B1 and OATP1B1 (IC_{50} values were 1.9 μ M and 2.0 μ M, respectively), while slightly lower effects were observed regarding OATP1B3 and OATP1A2 (IC_{50} values were 4.1 μ M and 5.4 μ M, respectively).




Figure 3. Inhibition of dye uptake in the presence of increasing AOH concentrations (0–20 μM) in A431 cells overexpressing human OATPs (see experimental details in Section 2.5; $n = 3$; * $p < 0.05$, ** $p < 0.01$).

To determine whether AOH is a potential transported substrate of OATP1B1, AOH uptake was investigated in OATP expressing and mock transfected A431 cells. In these experiments, cells were incubated with increasing concentrations of AOH, then the cellular mycotoxin concentration was quantified by HPLC-FLD. OATP1B1 expressing cells showed higher cellular AOH levels compared to mock cells (Figure 4), suggesting the OATP1B1-mediated transport of the mycotoxin. However, likely due to the rapid and significant membrane association of the mycotoxin, we also found relatively high levels of AOH in the mock cells. Therefore, to confirm the involvement of OATP1B1 in the cellular uptake of AOH, further experiments were performed.




Figure 4. AOH concentrations in A431 cell extracts after 15 min incubation with 2, 5, or 10 μM mycotoxin solutions. AOH was quantified by HPLC-FLD (see experimental details in Sections 2.6 and 2.7; $n = 6$; * $p < 0.05$, ** $p < 0.01$).

Recently, a novel method, termed as competitive counterflow (CCF), was established that can distinguish transported substrates and non-transported inhibitors of OATP2B1 or OATP1A2 [39,40]. The method is based on the exchanger function of OATPs, by which even

large organic substrates can be swapped between the opposite sites of the cell membrane. Lately, using the fluorogenic substrate 8-acetoxy-1,3,6-trisulfofopyrene (Ace), we developed the CCF for OATP1B1 [33]. The method comprises two steps. First, the cells are loaded with Ace to a steady state (by the function of OATP1B1). Next, the investigated compound (AOH in the current study) is added. The addition of a substrate (E1S used here as a reference substrate) at high enough amounts (ten-fold of its IC_{50} value) triggers the efflux of the probe, leading to a decrease in the fluorescence signal in the CCF (Figure 5, top) and not inhibiting efflux (Figure 5, bottom). On the other hand, non-transported inhibitors (we used formaldehyde, a chemical crosslinker here) blocks the efflux of the probe (Figure 5, bottom) and there is no change in the fluorescence in the CCF. Figure 5 indicates that AOH added in excess (already at two-fold of its IC_{50}) generated a decrease in the fluorescence signal in the CCF, while not inhibiting efflux. These observations indicate that AOH is a potential substrate of OATP1B1.




Figure 5. Effects of AOH on dye transport in CCF (top) and efflux (bottom) assays (see experimental details in Section 2.8; $n = 3$; ** $p < 0.01$).

Only limited information is available regarding the interactions of mycotoxins with OATP transporters. Nevertheless, based on previous studies, certain OATPs may have significant involvement in the tissue uptake and accumulation of mycotoxins ochratoxin

A [21,24] and deoxynivalenol [41]. In our study, AOH showed strong, concentration-dependent inhibitory action on each OATP transporter tested ($IC_{50} = 1.9$ to $5.4 \mu\text{M}$). Therefore, the potential involvement of OATP1B1 in the cellular uptake of the mycotoxin was also examined. We measured higher concentrations of AOH in OATP1B1 expressing vs. the mock cells (Figure 4). In addition, counterflow and efflux assays were performed, where we could distinguish non-transported inhibitors and transported substrates of OATP1B1 [33]. In these experiments, AOH behaved similarly to the reference substrate E1S (Figure 5). These observations strongly suggest that AOH is not only an inhibitor but also a substrate of the OATP1B1 transporter.

4. Conclusions

In summary, CYP enzymes and OATP transporters are involved in the pharmacokinetics and/or toxicokinetics of several drugs and xenobiotics. Since toxicokinetic interactions of mycotoxin AOH have barely been characterized, in the current study, we aimed to investigate its interactions with CYP (1A2, 2C9, 2C19, 2D6, and 3A4) enzymes and OATP (1A2, 1B1, 1B3, and 2B1) transporters. Considering the low oral bioavailability of AOH as well as its typically nanomolar concentrations in the circulation [4,9,10], it seems to be unlikely that AOH can considerably interfere with the CYP-catalyzed biotransformation and/or the OATP-mediated transport of drugs. However, AOH concentration may be significantly higher in the intestinal tract than in the circulation, suggesting the possible inhibition of OATP2B1-mediated absorption of certain compounds. In addition, the involvement of OATPs in the tissue uptake of mycotoxin AOH may have toxicological importance. Considering the endocrine disruptor effects of AOH [4,7], further studies are reasonable to test the potential role of OATP transporters in the uptake of the mycotoxins into the target organs.

Author Contributions: Conceptualization, C.Ö.-L. and M.P.; data curation, M.P.; formal analysis, E.F.-N., O.U. and Á.D.; funding acquisition, C.Ö.-L. and M.P.; investigation, E.F.-N., O.U. and Á.D.; methodology, E.F.-N., C.Ö.-L. and M.P.; supervision, C.Ö.-L. and M.P.; validation, C.Ö.-L. and M.P.; writing—original draft, C.Ö.-L. and M.P. All authors have read and agreed to the published version of the manuscript.

Funding: M.P. is thankful for the support of the János Bolyai Research Scholarship of the Hungarian Academy of Sciences and the Hungarian National Research, Development and Innovation Office (FK138184). This work was also supported by research grants of the Hungarian National Research, Development and Innovation Office (FK128751 and K138518, C.Ö.-L.). O.U. is a grantee of the ÚNKP fellowship (ÚNKP-20-3). This work was supported by the KDP-2021 program of the Ministry of Innovation and Technology from the source of the National Research, Development and Innovation Fund (O.U.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data will be made available on request.

Acknowledgments: The authors thank Katalin Fábrián for her excellent assistance in the experimental work.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Šarkanj, B.; Ezekiel, C.N.; Turner, P.C.; Abia, W.A.; Rychlik, M.; Krska, R.; Sulyok, M.; Warth, B. Ultra-sensitive, stable isotope assisted quantification of multiple urinary mycotoxin exposure biomarkers. *Anal. Chim. Acta* **2018**, *1019*, 84–92. [[CrossRef](#)] [[PubMed](#)]
2. Pinto, V.E.F.; Patriarca, A. Alternaria species and their associated mycotoxins. In *Mycotoxigenic Fungi*; Moretti, A., Scusa, A., Eds.; Humana Press Inc.: Totowa, NJ, USA, 2016; pp. 13–32. [[CrossRef](#)]
3. Asam, S.; Konitzer, K.; Rychlik, M. Precise determination of the Alternaria mycotoxins alternariol and alternariol monomethyl ether in cereal, fruit and vegetable products using stable isotope dilution assays. *Mycotoxin. Res.* **2011**, *27*, 23–28. [[CrossRef](#)] [[PubMed](#)]

4. EFSA on Contaminants in the Food Chain. Scientific Opinion on the risks for animal and public health related to the presence of *Alternaria* toxins in feed and food. *EFSA J.* **2011**, *9*, 2407. [[CrossRef](#)]
5. Ostry, V. *Alternaria* mycotoxins: An overview of chemical characterization, producers, toxicity, analysis and occurrence in foodstuffs. *World Mycotoxin J.* **2008**, *1*, 175–188. [[CrossRef](#)]
6. Dall'Asta, C.; Cirlini, M.; Falavigna, C. Mycotoxins from *Alternaria*: Toxicological implications. *Adv. Mol. Toxicol.* **2014**, *8*, 107–121. [[CrossRef](#)]
7. Solhaug, A.; Eriksen, G.S.; Holme, J.A. Mechanisms of action and toxicity of the mycotoxin alternariol: A review. *Basic Clin. Pharmacol. Toxicol.* **2016**, *119*, 533–539. [[CrossRef](#)] [[PubMed](#)]
8. Pfeiffer, E.; Schebb, N.H.; Podlech, J.; Metzler, M. Novel oxidative in vitro metabolites of the mycotoxins alternariol and alternariol methyl ether. *Mol. Nutr. Food Res.* **2007**, *51*, 307–316. [[CrossRef](#)] [[PubMed](#)]
9. Schuchardt, S.; Ziemann, C.; Hansen, T. Combined toxicokinetic and in vivo genotoxicity study on *Alternaria* toxins. *EFSA Support. Publ.* **2014**, *11*, 679E. [[CrossRef](#)]
10. Puntschner, H.; Aichinger, G.; Grabher, S.; Attakpah, E.; Krüger, F.; Tillmann, K.; Motschnig, T.; Hohenbichler, J.; Braun, D.; Plasenzotti, R.; et al. Bioavailability, metabolism, and excretion of a complex *Alternaria* culture extract versus altertoxin II: A comparative study in rats. *Arch. Toxicol.* **2019**, *93*, 3153–3167. [[CrossRef](#)]
11. Guengerich, F.P. Cytochrome P450 and chemical toxicology. *Chem. Res. Toxicol.* **2008**, *21*, 70–83. [[CrossRef](#)]
12. Haddad, A.; Davis, M.; Lagman, R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: Review and recommendations for avoiding adverse drug interactions. *Support. Care Cancer* **2007**, *15*, 251–257. [[CrossRef](#)] [[PubMed](#)]
13. Deng, J.; Zhao, L.; Zhang, N.; Karrow, N.A.; Krumm, C.S.; Qi, D.; Sun, L. Aflatoxin B1 metabolism: Regulation by phase I and II metabolizing enzymes and chemoprotective agents. *Mutat. Res. Rev. Mutat. Res.* **2018**, *778*, 79–89. [[CrossRef](#)] [[PubMed](#)]
14. Rogowska, A.; Pomastowski, P.; Sagandykova, G.; Buszewski, B. Zearalenone and its metabolites: Effect on human health, metabolism and neutralisation methods. *Toxicon* **2019**, *162*, 46–56. [[CrossRef](#)] [[PubMed](#)]
15. Tao, Y.; Xie, S.; Xu, F.; Liu, A.; Wang, Y.; Chen, D.; Pan, Y.; Huang, L.; Peng, D.; Wang, X.; et al. Ochratoxin A: Toxicity, oxidative stress and metabolism. *Food Chem. Toxicol.* **2018**, *112*, 320–331. [[CrossRef](#)] [[PubMed](#)]
16. Schreck, I.; Deigendesch, U.; Burkhardt, B.; Marko, D.; Weiss, C. The *Alternaria* mycotoxins alternariol and alternariol methyl ether induce cytochrome P450 1A1 and apoptosis in murine hepatoma cells dependent on the aryl hydrocarbon receptor. *Arch. Toxicol.* **2012**, *86*, 625–632. [[CrossRef](#)]
17. Hagenbuch, B.; Meier, P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. *Pflügers Arch.* **2004**, *447*, 653–665. [[CrossRef](#)]
18. Hagenbuch, B.; Stieger, B. The SLCO (former SLC21) superfamily of transporters. *Mol. Asp. Med.* **2013**, *34*, 396–412. [[CrossRef](#)]
19. Hagenbuch, B.; Gui, C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. *Xenobiotica* **2008**, *38*, 778–801. [[CrossRef](#)]
20. Mohos, V.; Fliszár-Nyúl, E.; Ungvári, O.; Bakos, É.; Kuffa, K.; Bencsik, T.; Zsidó, B.Z.; Hetényi, C.; Telbisz, Á.; Özvegy-Laczka, C.; et al. Effects of chrysin and its major conjugated metabolites chrysin-7-sulfate and chrysin-7-glucuronide on cytochrome P450 enzymes and on OATP, P-gp, BCRP, and MRP2 transporters. *Drug Metab. Dispos.* **2020**, *48*, 1064–1073. [[CrossRef](#)]
21. Wang, J.; Gan, C.; Qi, X.; Lebb, M.C.; Schinkel, A.H. Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice. *Toxicol. Appl. Pharmacol.* **2020**, *401*, 115072. [[CrossRef](#)]
22. Stieger, B.; Heger, M.; de Graaf, W.; Paumgartner, G.; van Gulik, T. The emerging role of transport systems in liver function tests. *Eur. J. Pharmacol.* **2012**, *675*, 1–5. [[CrossRef](#)] [[PubMed](#)]
23. Svoboda, M.; Riha, J.; Wlcek, K.; Jaeger, W.; Thalhammer, T. Organic anion transporting polypeptides (OATPs): Regulation of expression and function. *Curr. Drug Metab.* **2011**, *12*, 139–153. [[CrossRef](#)] [[PubMed](#)]
24. Kontaxi, M.; Eckhardt, U.; Hagenbuch, B.; Stieger, B.; Meier, P.J.; Petzinger, E. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. *J. Pharmacol. Exp. Ther.* **1996**, *279*, 1507–1513.
25. Mohos, V.; Fliszár-Nyúl, E.; Lemli, B.; Zsidó, B.Z.; Hetényi, C.; Mladěnka, P.; Horký, P.; Pour, M.; Poór, M. Testing the pharmacokinetic interactions of 24 colonic flavonoid metabolites with human serum albumin and cytochrome P450 enzymes. *Biomolecules* **2020**, *10*, 409. [[CrossRef](#)] [[PubMed](#)]
26. Fliszár-Nyúl, E.; Mohos, V.; Bencsik, T.; Lemli, B.; Kunsági-Máté, S.; Poór, M. Interactions of 7,8-dihydroxyflavone with serum albumin as well as with CYP2C9, CYP2C19, CYP3A4, and xanthine oxidase biotransformation enzymes. *Biomolecules* **2019**, *9*, 655. [[CrossRef](#)] [[PubMed](#)]
27. Mohos, V.; Bencsik, T.; Boda, G.; Fliszár-Nyúl, E.; Lemli, B.; Kunsági-Máté, S.; Poór, M. Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes. *Biomed. Pharmacother.* **2018**, *107*, 777–784. [[CrossRef](#)]
28. Faisal, Z.; Mohos, V.; Fliszár-Nyúl, E.; Valentová, K.; Kaňová, K.; Lemli, B.; Kunsági-Máté, S.; Poór, M. Interaction of silymarin components and their sulfate metabolites with human serum albumin and cytochrome P450 (2C9, 2C19, 2D6, and 3A4) enzymes. *Biomed. Pharmacother.* **2021**, *138*, 111459. [[CrossRef](#)]
29. Bakos, É.; Német, O.; Patik, I.; Kucsma, N.; Várady, G.; Szakács, G.; Özvegy-Laczka, C. A novel fluorescence-based functional assay for human OATP1A2 and OATP1C1 identifies interaction between third-generation P-gp inhibitors and OATP1A2. *FEBS J.* **2020**, *287*, 2468–2485. [[CrossRef](#)]

30. Patik, I.; Székely, V.; Német, O.; Szepesi, Á.; Kucsma, N.; Várady, G.; Szakács, G.; Bakos, É.; Özvegy-Laczka, C. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1. *Sci. Rep.* **2018**, *8*, 2630. [[CrossRef](#)]
31. Székely, V.; Patik, I.; Ungvári, O.; Telbisz, Á.; Szakács, G.; Bakos, É.; Özvegy-Laczka, C. Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions. *Eur. J. Pharm. Sci.* **2020**, *151*, 105395. [[CrossRef](#)]
32. Fliszár-Nyúl, E.; Lemli, B.; Kunsági-Máté, S.; Poór, M. Effects of microenvironmental changes on the fluorescence signal of alternariol: Magnesium induces strong enhancement in the fluorescence of the mycotoxin. *Int. J. Mol. Sci.* **2021**, *22*, 8692. [[CrossRef](#)] [[PubMed](#)]
33. Ungvári, O.; Király, L.; Bakos, É.; Özvegy-Laczka, C. 8-acetoxy-trisulfopyrene as the first activatable fluorogenic probe for add-and-read assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1. *FASEB J.* **2021**, *35*, e21863. [[CrossRef](#)] [[PubMed](#)]
34. Kotsuma, M.; Hanzawa, H.; Iwata, Y.; Takahashi, K.; Tokui, T. Novel Binding Mode of the Acidic CYP2D6 Substrates Pactimibe and Its Metabolite R-125528. *Drug Metab. Disp.* **2008**, *36*, 1938–1943. [[CrossRef](#)] [[PubMed](#)]
35. Al-Harbi, S.A.; Abdulrahman, A.O.; Zamzami, M.A.; Khan, M.I. Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. *Front. Nutr.* **2021**, *8*, 647582. [[CrossRef](#)]
36. Kasimsetty, S.G.; Bialonska, D.; Reddy, M.K.; Thornton, C.; Willett, K.L.; Ferreira, D. Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. *J. Agric. Food Chem.* **2009**, *57*, 10636–10644. [[CrossRef](#)]
37. Schelstraete, W.; Devreese, M.; Croubels, S. Impact of subacute exposure to T-2 toxin and zearalenone on the pharmacokinetics of midazolam as CYP3A probe drug in a porcine animal model: A pilot study. *Front. Pharmacol.* **2019**, *10*, 399. [[CrossRef](#)]
38. Pfeiffer, E.; Burkhardt, B.; Altemöller, M.; Podlech, J.; Metzler, M. Activities of human recombinant cytochrome P450 isoforms and human hepatic microsomes for the hydroxylation of Alternaria toxins. *Mycotox. Res.* **2008**, *24*, 117–123. [[CrossRef](#)]
39. Schäfer, A.M.; Bock, T.; Meyer zu Schwabedissen, H.E. Establishment and validation of competitive counterflow as a method to detect substrates of the organic anion transporting polypeptide 2B1. *Mol. Pharm.* **2018**, *15*, 5501–5513. [[CrossRef](#)]
40. Schäfer, A.M.; Meyer zu Schwabedissen, H.E.; Bien-Möller, S.; Hubeny, A.; Vogelgesang, S.; Oswald, S.; Grube, M. OATP1A2 and OATP2B1 are interacting with dopamine-receptor agonists and antagonists. *Mol. Pharm.* **2020**, *17*, 1987–1995. [[CrossRef](#)]
41. Li, X.; Mu, P.; Wen, J.; Deng, Y. Carrier-mediated and energy-dependent uptake and efflux of deoxynivalenol in mammalian cells. *Sci. Rep.* **2017**, *7*, 5889. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.